Revisit Every OncLive On Air Episode From April 2025

OncLive On Air Podcast Recap

In case you missed any, below is a recap of the episodes of OncLive On Air® that aired in April 2025. Check out our podcast page for a full episode lineup and to stay up to date with all the latest releases!

ADC-Based Combinations Gain Momentum in Bladder Cancer Management: With Chandler Park, MD; and Vadim Koshkin, MD

In part 1 of this 3-part series with MedNews Week's Oncology Unplugged, host Chandler Park, MD, of Norton Cancer Institute in Louisville, Kentucky, invited Vadim Koshkin, MD, of the University of California, San Francisco (UCSF) School of Medicine and the UCSF Helen Diller Comprehensive Cancer Center, discussed exciting developments in bladder cancer management.

Comprehensive First-Line Bladder Cancer Treatment Begins With Careful Patient Selection: With Chandler Park, MD

In this episode of OncLive On Air, Chandler Park, MD, highlighted the components of the current frontline bladder cancer treatment paradigm, the anticipated evolution of this paradigm, and how frontline therapy choices influences treatment decision-making regarding subsequent lines of therapy.

AR Pathway Inhibition Refines Prostate Cancer Treatment Strategies: With Neal Shore, MD, FACS

In this episode, Neal Shore, MD, FACS, of the Carolina Urologic Research Center in Myrtle Beach, South Carolina, highlighted the significance of multidisciplinary meetings to collaborate regarding unmet needs for patients with prostate cancer, gaps in the treatment paradigm for improved treatment strategies, the evolution of neoadjuvant and adjuvant therapies, and the importance of imaging and biomarkers.

Innovative Research Raises Questions About the Role of ADCs in Bladder Cancer: With Chandler Park, MD; and Vadim Koshkin, MD

In part 2 of this 3-part series with MedNews Week's Oncology Unplugged, host Chandler Park, MD, was rejoined by Vadim Koshkin, MD, to talk through treatment sequencing and combination strategies for the continued use of antibody-drug conjugates for bladder cancer, the potential evolving role of sacituzimab govitecan-hziy (Trodelvy) in this disease space, and the development of new treatments for patients whose disease progresses on enfortumab vedotin-ejfv (Padcev) in combination with pembrolizumab (Keytruda).

Peer Support, Adaptability, and Self-Confidence Are Hallmarks of Successful Oncology Careers: With Liliana Bustamante, MD; and Jessica Stine, MD

In this episode, part of our Women in Oncology subseries, Liliana Bustamante, MD, and Jessica Stine, MD, both of Florida Cancer Specialists & Research Institute in Tampa, shared their unique oncology career journeys, the fulfilling aspects of treating patients with cancer, the significance of peer mentorship, and advice for juggling work-life balance.

Bladder-Sparing Strategies and ctDNA-Guided Strategies Take Center Stage in MIBC: With Chandler Park, MD; and Vadim Koshkin, MD

In the final part of this 3-part series with MedNews Week’s Oncology Unplugged, host Chandler Park, MD, was rejoined by Vadim Koshkin, MD, discussed practice-changing data from the phase 3 NIAGARA trial (NCT03732677) investigating perioperative durvalumab (Imfinzi) in combination with neoadjuvant chemotherapy in patients with resectable bladder cancer, as well as evolutions in the perioperative treatment armamentarium that may influence future treatment decision-making for these patients.

Social Media Unlocks New Avenues for Expanding Access to Oncology Education: With Chandler Park, MD; and Paul Hanona, MD

In part 1 of this 3-part series with MedNews Week's Oncology Unplugged, host Chandler Park, MD, was joined by Paul Hanona, MD, a content creator under the handle @doctordiscover. They shared influential aspects of Dr Hanona's social media platforms, the importance of social media for educating health care professionals and patients alike, and the challenges associated with treatment decision-making in light of oncology treatment advances.

Motivation and Consistency Are Key to Building a Successful Oncology Educational Platform: With Chandler Park, MD; and Paul Hanona, MD

In part 2 of this 3-part series with MedNews Week’s Oncology Unplugged, host Chandler Park, MD, was rejoined by Paul Hanona, MD, to talk through effective oncology social media strategies, simple recording equipment that makes a big splash on social media, and the importance of tailoring each piece of content to the specific audience of each platform.

Oncodetect MRD Test Aids Treatment Decision-Making in CRC and Other Solid Tumors: With Eric Christenson, MD

In this episode, Eric Christenson, MD, of the Johns Hopkins School of Medicine in Baltimore, Maryland, highlighted the clinical applications of the Oncodetect test, which is available for use in molecular residual disease detection in patients with solid tumors; top data from the Alpha-CORRECT study that validated this assay; and OncoDetect’s prognostic value.

Radioligand Therapy Advances Represent the Future of mCRPC Treatment: With Daniel P. Petrylak, MD

In this episode, Daniel P. Petrylak, MD, of the Yale School of Medicine and Smilow Cancer Hospital in New Haven, Connecticut, explained the current role for Lutetium Lu 177 vipivotide tetraxetan (Pluvicto) in metastatic castration-resistant prostate cancer management, the radioligand therapy’s safety profile, the significance of harnessing multidisciplinary collaboration to deliver this therapy to patients, and future investigations of this class of therapy in combination with other types of agents.

Disease Features and Treatment Intolerance Inform Pirtobrutinib Use in Pretreated CLL: With Nicole Lamanna, MD

In this episode, Nicole Lamanna, MD, of the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia University Irving Medical Center in New York, New York, noted disease features and patient characteristics that inform the decision to initiate pirtobrutinib (Jaypirca) in patients with chronic lymphocytic leukemia, as well as clinical features that inform the use of noncovalent BTK inhibitors in this disease.

Advancing Brain Metastases Research and Mentorship in Breast Oncology: With D. Ross Camidge, MD, PhD; Nancy U. Lin, MD

In this episode of How This Is Building Me, host D. Ross Camidge, MD, PhD, sat down with Nancy U. Lin, MD, of Dana-Farber Cancer Institute in Boston, Massachusetts, to talk through Dr Lin's role in developing targeted therapies for patients with breast cancer, the importance of systemic therapy in the management of brain metastases, and the value in mentoring up-and-coming oncologists.